东菱迪夫联合依达拉奉治疗进展性脑梗死疗效观察

目的观察依达拉奉联合东菱迪夫(DF-521)治疗急性脑梗死的有效性和安全性。方法采用随机、平行、设立对照组对照试验,选择发病48h内的ACI患者61例,随机分成治疗组和对照组。治疗组给予依达拉奉30mg静滴,2次/d,共10d,DF-521 10U、5 U、5U静滴,分别于第1、3、5d应用,共3次;依达拉奉组给予依达拉奉30mg静滴,2次/d,共10d,阿司匹林150mg口服,1次/d;对照组给予步复迈250ml静滴,1次/d,共10d,大剂量盐酸纳洛酮2 g静滴,1次/d,共10d,阿司匹林150mg口服,1次/d。根据脑卒中病人临床疗效评分标准进行疗效评定。结果4周后治疗组NIHSS及ADL均明显高于对照组,治疗后纤维蛋白原(FDP)较前明显下降,而血小板、红细胞比积、出凝血时间及肾功能无明显改变;并且治疗组无明显不良反应。结论依达拉奉联合东菱迪夫治疗进展性脑梗死安全有效。

Clinical effect of Edaravone combined Batroxobin for acute cerebral infarction

Objective To verify the efficacy and safety of Edaravone combined Batroxobin for acute cerebral infarction(ACI).Methods The parallel and controlled study was performed on ACI patients(61cases),enrolled within 48 hours of onset.They were randomly divided into treatment group(32 patients) and control group(33 patients).Treatment group was allocated Batroxobin 10U,once daily,for 3 days,and Edaravone 30mg,twice a day,for 10 days.Control group was allocated carthami(20ml) and Vitamin C(4g)separately,once daily,for 10 days.Meanwhile Aspirin 150 mg and Vitamin E 0.1g were taken per os once daily.Therapeutic effect was evaluated on the basis of effect scale standard of stroke.And then whole blood viscosity,fibrinogen,platelet,hemocyte specific volume,bleeding time,clotting time,liver function and renal function were detected.Results After four weeks,the basical cure rate(34.4%)and remarkable progress rate(43.8%)in treatment groups were higher obviously than those of control group(15.1%,18.2%).After treatment,whole blood viscosity and fibrinogen decreased dramatically,while platelet,hemo-cyte specific volume,bleeding time,clotting time,liver function and renal function did not change obviously.There was no distinct adverse reaction in treatment group. Conclusion Batroxobin combined Edaravone is an effective and safe method for acute cerebral infarction.